FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800379460> ?p ?o ?g. }

• W2800379460 endingPage "542" @default.
• W2800379460 startingPage "536" @default.
• W2800379460 abstract "Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assessed real-world safety and efficacy of LDV/SOF with or without ribavirin (RBV) in GT4-infected patients with compensated and decompensated cirrhosis. Patients & Methods This observational cohort (n = 213) included GT4 treatment-naïve (59.6%) and -experienced (40.4%) patients with advanced fibrosis (F3, Metavir; n = 30), compensated (F4, n = 135) and decompensated cirrhosis (n = 48) treated for 12 (n = 202) or 24 weeks (n = 11) with LDV/SOF. RBV was dosed by physician discretion between 600–1200 mg daily. Patients with prior DAA failure were excluded from the analysis. The primary efficacy endpoint was sustained virologic response 12 weeks after treatment (SVR12) on an intention-to-treat analysis, and occurrence of serious adverse events (SAEs). Results The mean age of the overall cohort was 59.6 ± 12.1 years and 125 (58.7) were female. Overall, 197 (92.5%) of the patients achieved SVR12, including 93.3% of F3 fibrosis, 93.3% of compensated cirrhotics and 89.6% of the decompensated cirrhotics (P = 0.686). Addition of RBV (68.5%) did not enhance efficacy (91.8% vs. 94.0% without RBV, P = 0.563), including in F3 fibrosis, compensated and decompensated cirrhosis (P > 0.05, for all). There was no difference in SVR12 rates with 24 and 12 weeks therapy (90.9% and 92.6%, respectively; P = 0.586). Treatment failure (n = 16) was mostly related to relapse (n = 11), while on-treatment death (n = 3) and breakthrough (n = 2) comprised a minority. SAEs occurred in 9 (4.2%) patients requiring early treatment discontinuation in 4 (3 on-treatment deaths and 1 pregnancy). Conclusion LDV/SOF therapy yielded high SVR12 rates in both compensated and decompensated cirrhotic GT4 patients. The addition of RBV to this regimen did not improve efficacy. The safety profile of this regimen was comparable with that reported for other HCV genotypes." @default.
• W2800379460 created "2018-05-17" @default.
• W2800379460 creator A5014120455 @default.
• W2800379460 creator A5016683919 @default.
• W2800379460 creator A5022337388 @default.
• W2800379460 creator A5023770809 @default.
• W2800379460 creator A5029743712 @default.
• W2800379460 creator A5030879149 @default.
• W2800379460 creator A5035295606 @default.
• W2800379460 creator A5038898216 @default.
• W2800379460 creator A5040685247 @default.
• W2800379460 creator A5045725016 @default.
• W2800379460 creator A5047245511 @default.
• W2800379460 creator A5048776832 @default.
• W2800379460 creator A5048877999 @default.
• W2800379460 creator A5049281923 @default.
• W2800379460 creator A5058815535 @default.
• W2800379460 creator A5060690302 @default.
• W2800379460 creator A5068362077 @default.
• W2800379460 creator A5069112778 @default.
• W2800379460 creator A5072952036 @default.
• W2800379460 creator A5077039400 @default.
• W2800379460 creator A5080409767 @default.
• W2800379460 creator A5090751447 @default.
• W2800379460 creator A5091667161 @default.
• W2800379460 date "2018-06-01" @default.
• W2800379460 modified "2023-09-27" @default.
• W2800379460 title "Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4–infected patients with advanced liver fibrosis and decompensated cirrhosis" @default.
• W2800379460 cites W1571790880 @default.
• W2800379460 cites W1977300462 @default.
• W2800379460 cites W1990827144 @default.
• W2800379460 cites W2029260455 @default.
• W2800379460 cites W2092646281 @default.
• W2800379460 cites W2116998649 @default.
• W2800379460 cites W2133036275 @default.
• W2800379460 cites W2151063300 @default.
• W2800379460 cites W2277396963 @default.
• W2800379460 cites W2340138588 @default.
• W2800379460 cites W2419279616 @default.
• W2800379460 cites W2467146687 @default.
• W2800379460 cites W2510132533 @default.
• W2800379460 cites W2578013986 @default.
• W2800379460 cites W2589446171 @default.
• W2800379460 cites W2741049796 @default.
• W2800379460 cites W2789350771 @default.
• W2800379460 cites W4211243282 @default.
• W2800379460 doi "https://doi.org/10.1016/j.jinf.2018.04.001" @default.
• W2800379460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29742470" @default.
• W2800379460 hasPublicationYear "2018" @default.
• W2800379460 type Work @default.
• W2800379460 sameAs 2800379460 @default.
• W2800379460 citedByCount "15" @default.
• W2800379460 countsByYear W28003794602019 @default.
• W2800379460 countsByYear W28003794602020 @default.
• W2800379460 countsByYear W28003794602021 @default.
• W2800379460 countsByYear W28003794602022 @default.
• W2800379460 crossrefType "journal-article" @default.
• W2800379460 hasAuthorship W2800379460A5014120455 @default.
• W2800379460 hasAuthorship W2800379460A5016683919 @default.
• W2800379460 hasAuthorship W2800379460A5022337388 @default.
• W2800379460 hasAuthorship W2800379460A5023770809 @default.
• W2800379460 hasAuthorship W2800379460A5029743712 @default.
• W2800379460 hasAuthorship W2800379460A5030879149 @default.
• W2800379460 hasAuthorship W2800379460A5035295606 @default.
• W2800379460 hasAuthorship W2800379460A5038898216 @default.
• W2800379460 hasAuthorship W2800379460A5040685247 @default.
• W2800379460 hasAuthorship W2800379460A5045725016 @default.
• W2800379460 hasAuthorship W2800379460A5047245511 @default.
• W2800379460 hasAuthorship W2800379460A5048776832 @default.
• W2800379460 hasAuthorship W2800379460A5048877999 @default.
• W2800379460 hasAuthorship W2800379460A5049281923 @default.
• W2800379460 hasAuthorship W2800379460A5058815535 @default.
• W2800379460 hasAuthorship W2800379460A5060690302 @default.
• W2800379460 hasAuthorship W2800379460A5068362077 @default.
• W2800379460 hasAuthorship W2800379460A5069112778 @default.
• W2800379460 hasAuthorship W2800379460A5072952036 @default.
• W2800379460 hasAuthorship W2800379460A5077039400 @default.
• W2800379460 hasAuthorship W2800379460A5080409767 @default.
• W2800379460 hasAuthorship W2800379460A5090751447 @default.
• W2800379460 hasAuthorship W2800379460A5091667161 @default.
• W2800379460 hasConcept C126322002 @default.
• W2800379460 hasConcept C197934379 @default.
• W2800379460 hasConcept C203014093 @default.
• W2800379460 hasConcept C203092338 @default.
• W2800379460 hasConcept C2522874641 @default.
• W2800379460 hasConcept C2775999097 @default.
• W2800379460 hasConcept C2776408679 @default.
• W2800379460 hasConcept C2776455275 @default.
• W2800379460 hasConcept C2777214474 @default.
• W2800379460 hasConcept C2778390639 @default.
• W2800379460 hasConcept C2780040827 @default.
• W2800379460 hasConcept C535046627 @default.
• W2800379460 hasConcept C71924100 @default.
• W2800379460 hasConcept C90924648 @default.
• W2800379460 hasConceptScore W2800379460C126322002 @default.
• W2800379460 hasConceptScore W2800379460C197934379 @default.
• W2800379460 hasConceptScore W2800379460C203014093 @default.
• W2800379460 hasConceptScore W2800379460C203092338 @default.

• next